Click here to get full coverage on Kymera Therapeutics (KYMR) Sees 4% Drop in Stock Price - GuruFocus

Kymera Therapeutics (KYMR) Sees 4% Drop in Stock Price  GuruFocus

Kymera Therapeutics (KYMR) Sees 4% Drop in Stock Price - GuruFocus

Click here to get full coverage on Insider Buying: Smart Money Just Spent +$100M on These 3 Stocks - MarketBeat

Insider Buying: Smart Money Just Spent +$100M on These 3 Stocks  MarketBeat

Insider Buying: Smart Money Just Spent +$100M on These 3 Stocks - MarketBeat

Click here to get full coverage on Kymera Therapeutics (KYMR) Valuation After KT-621 Fast Track Win and Strong Phase 1b BroADen Trial Data - Yahoo Finance

Kymera Therapeutics (KYMR) Valuation After KT-621 Fast Track Win and Strong Phase 1b BroADen Trial Data  Yahoo Finance

Kymera Therapeutics (KYMR) Valuation After KT-621 Fast Track Win and Strong Phase 1b BroADen Trial Data - Yahoo Finance

Click here to get full coverage on Kymera Therapeutics (KYMR) stock falls today as biotech slips — what traders are watching - ts2.tech

Kymera Therapeutics (KYMR) stock falls today as biotech slips — what traders are watching  ts2.tech

Kymera Therapeutics (KYMR) stock falls today as biotech slips — what traders are watching - ts2.tech

Click here to get full coverage on The Technical Signals Behind (KYMR) That Institutions Follow - Stock Traders Daily

The Technical Signals Behind (KYMR) That Institutions Follow  Stock Traders Daily

The Technical Signals Behind (KYMR) That Institutions Follow - Stock Traders Daily

Click here to get full coverage on RBC Capital Maintains Kymera Therapeutics (KYMR) Outperform Recommendation - Nasdaq

RBC Capital Maintains Kymera Therapeutics (KYMR) Outperform Recommendation  Nasdaq

RBC Capital Maintains Kymera Therapeutics (KYMR) Outperform Recommendation - Nasdaq

Click here to get full coverage on Why Is KYMR Stock Up 54% Today? - Stocktwits

Why Is KYMR Stock Up 54% Today?  Stocktwits

Why Is KYMR Stock Up 54% Today? - Stocktwits

Click here to get full coverage on This Drugmaker's Stock Is Soaring Over 40% Monday - Investopedia

This Drugmaker's Stock Is Soaring Over 40% Monday  Investopedia

This Drugmaker's Stock Is Soaring Over 40% Monday - Investopedia

Click here to get full coverage on Kymera Therapeutics (KYMR) Stock Surges on Surprisingly Strong Clinical Trial Results - TipRanks

Kymera Therapeutics (KYMR) Stock Surges on Surprisingly Strong Clinical Trial Results  TipRanks

Kymera Therapeutics (KYMR) Stock Surges on Surprisingly Strong Clinical Trial Results - TipRanks

Click here to get full coverage on Kymera Therapeutics Announces Pricing of $602 Million Public Offering of Common Stock | KYMR Stock News - Quiver Quantitative

Kymera Therapeutics Announces Pricing of $602 Million Public Offering of Common Stock | KYMR Stock News  Quiver Quantitative

Kymera Therapeutics Announces Pricing of $602 Million Public Offering of Common Stock | KYMR Stock News - Quiver Quantitative

Click here to get full coverage on KYMR Stock Surges on Upbeat Data From KT-621 Atopic Dermatitis Study - Finviz

KYMR Stock Surges on Upbeat Data From KT-621 Atopic Dermatitis Study  Finviz

KYMR Stock Surges on Upbeat Data From KT-621 Atopic Dermatitis Study - Finviz

Click here to get full coverage on Kymera Therapeutics (NASDAQ:KYMR) CEO Nello Mainolfi Sells 30,000 Shares - MarketBeat

Kymera Therapeutics (NASDAQ:KYMR) CEO Nello Mainolfi Sells 30,000 Shares  MarketBeat

Kymera Therapeutics (NASDAQ:KYMR) CEO Nello Mainolfi Sells 30,000 Shares - MarketBeat

Click here to get full coverage on The Bull Case For Kymera Therapeutics (KYMR) Could Change Following Early KT-621 STAT6 Trial Data - Yahoo Finance

The Bull Case For Kymera Therapeutics (KYMR) Could Change Following Early KT-621 STAT6 Trial Data  Yahoo Finance

The Bull Case For Kymera Therapeutics (KYMR) Could Change Following Early KT-621 STAT6 Trial Data - Yahoo Finance

Click here to get full coverage on B. Riley Securities Maintains Kymera Therapeutics (KYMR) Buy Recommendation - Nasdaq

B. Riley Securities Maintains Kymera Therapeutics (KYMR) Buy Recommendation  Nasdaq

B. Riley Securities Maintains Kymera Therapeutics (KYMR) Buy Recommendation - Nasdaq

Click here to get full coverage on Kymera (KYMR) Jumps to All-Time High as Eczema Treatment Results Impress - Yahoo Finance

Kymera (KYMR) Jumps to All-Time High as Eczema Treatment Results Impress  Yahoo Finance

Kymera (KYMR) Jumps to All-Time High as Eczema Treatment Results Impress - Yahoo Finance

Click here to get full coverage on Bank of America Issues Positive Forecast for Kymera Therapeutics (NASDAQ:KYMR) Stock Price - MarketBeat

Bank of America Issues Positive Forecast for Kymera Therapeutics (NASDAQ:KYMR) Stock Price  MarketBeat

Bank of America Issues Positive Forecast for Kymera Therapeutics (NASDAQ:KYMR) Stock Price - MarketBeat

Click here to get full coverage on Mizuho Maintains Kymera Therapeutics (KYMR) Outperform Recommendation - Nasdaq

Mizuho Maintains Kymera Therapeutics (KYMR) Outperform Recommendation  Nasdaq

Mizuho Maintains Kymera Therapeutics (KYMR) Outperform Recommendation - Nasdaq

Click here to get full coverage on Kymera Therapeutics, Inc. (KYMR) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance

Kymera Therapeutics, Inc. (KYMR) Reports Q3 Loss, Misses Revenue Estimates  Yahoo Finance

Kymera Therapeutics, Inc. (KYMR) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance

Click here to get full coverage on Why Kymera (KYMR) Could Be One of Biotech’s Most Interesting Growth Stories? - Yahoo Finance

Why Kymera (KYMR) Could Be One of Biotech’s Most Interesting Growth Stories?  Yahoo Finance

Why Kymera (KYMR) Could Be One of Biotech’s Most Interesting Growth Stories? - Yahoo Finance

Click here to get full coverage on How Investors Are Reacting To Kymera Therapeutics (KYMR) Preclinical Data on Oral IRF5 Degrader in Lupus and RA - Yahoo Finance

How Investors Are Reacting To Kymera Therapeutics (KYMR) Preclinical Data on Oral IRF5 Degrader in Lupus and RA  Yahoo Finance

How Investors Are Reacting To Kymera Therapeutics (KYMR) Preclinical Data on Oral IRF5 Degrader in Lupus and RA - Yahoo Finance

Click here to get full coverage on Kymera Therapeutics (NASDAQ:KYMR) Director Buys $172,499,918.00 in Stock - MarketBeat

Kymera Therapeutics (NASDAQ:KYMR) Director Buys $172,499,918.00 in Stock  MarketBeat

Kymera Therapeutics (NASDAQ:KYMR) Director Buys $172,499,918.00 in Stock - MarketBeat

Click here to get full coverage on Kymera Therapeutics (KYMR): Exploring Valuation Following Recent Share Price Momentum - Yahoo Finance

Kymera Therapeutics (KYMR): Exploring Valuation Following Recent Share Price Momentum  Yahoo Finance

Kymera Therapeutics (KYMR): Exploring Valuation Following Recent Share Price Momentum - Yahoo Finance

Click here to get full coverage on Kymera’s KT-621 Shines: Phase 1b Data Boosts Momentum (NASDAQ:KYMR) - Seeking Alpha

Kymera’s KT-621 Shines: Phase 1b Data Boosts Momentum (NASDAQ:KYMR)  Seeking Alpha

Kymera’s KT-621 Shines: Phase 1b Data Boosts Momentum (NASDAQ:KYMR) - Seeking Alpha

Click here to get full coverage on Squarepoint Ops LLC Cuts Position in Kymera Therapeutics, Inc. $KYMR - MarketBeat

Squarepoint Ops LLC Cuts Position in Kymera Therapeutics, Inc. $KYMR  MarketBeat

Squarepoint Ops LLC Cuts Position in Kymera Therapeutics, Inc. $KYMR - MarketBeat

Click here to get full coverage on Kymera Therapeutics, Inc. (KYMR) May Report Negative Earnings: Know the Trend Ahead of Q3 Release - Yahoo Finance

Kymera Therapeutics, Inc. (KYMR) May Report Negative Earnings: Know the Trend Ahead of Q3 Release  Yahoo Finance

Kymera Therapeutics, Inc. (KYMR) May Report Negative Earnings: Know the Trend Ahead of Q3 Release - Yahoo Finance

Click here to get full coverage on Kymera Therapeutics (KYMR) Stock Rises Sharply by 51% - GuruFocus

Kymera Therapeutics (KYMR) Stock Rises Sharply by 51%  GuruFocus

Kymera Therapeutics (KYMR) Stock Rises Sharply by 51% - GuruFocus

Click here to get full coverage on Kymera Therapeutics Inc (KYMR) Q3 2025 Earnings Report Preview: What to Look For - Yahoo Finance

Kymera Therapeutics Inc (KYMR) Q3 2025 Earnings Report Preview: What to Look For  Yahoo Finance

Kymera Therapeutics Inc (KYMR) Q3 2025 Earnings Report Preview: What to Look For - Yahoo Finance

Click here to get full coverage on Kymera Therapeutics (NASDAQ: KYMR) to share KT-621 Phase 1b AD results Dec. 8 - Stock Titan

Kymera Therapeutics (NASDAQ: KYMR) to share KT-621 Phase 1b AD results Dec. 8  Stock Titan

Kymera Therapeutics (NASDAQ: KYMR) to share KT-621 Phase 1b AD results Dec. 8 - Stock Titan

Click here to get full coverage on HC Wainwright & Co. Elevates Kymera Therapeutics (KYMR) Price Ta - GuruFocus

HC Wainwright & Co. Elevates Kymera Therapeutics (KYMR) Price Ta  GuruFocus

HC Wainwright & Co. Elevates Kymera Therapeutics (KYMR) Price Ta - GuruFocus

Click here to get full coverage on KYMR: B. Riley Securities Raises Price Target for Kymera Therape - GuruFocus

KYMR: B. Riley Securities Raises Price Target for Kymera Therape  GuruFocus

KYMR: B. Riley Securities Raises Price Target for Kymera Therape - GuruFocus

Click here to get full coverage on $KYMR stock is up 39% today. Here's what we see in our data. - Quiver Quantitative

$KYMR stock is up 39% today. Here's what we see in our data.  Quiver Quantitative

$KYMR stock is up 39% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Kymera Therapeutics (NASDAQ:KYMR) Shares Down 3.4% - Here's What Happened - MarketBeat

Kymera Therapeutics (NASDAQ:KYMR) Shares Down 3.4% - Here's What Happened  MarketBeat

Kymera Therapeutics (NASDAQ:KYMR) Shares Down 3.4% - Here's What Happened - MarketBeat

Click here to get full coverage on New Analyst Forecast: $KYMR Given $112 Price Target - Quiver Quantitative

New Analyst Forecast: $KYMR Given $112 Price Target  Quiver Quantitative

New Analyst Forecast: $KYMR Given $112 Price Target - Quiver Quantitative

Click here to get full coverage on Kymera Therapeutics (KYMR) Price Target Increased by 11.33% to 77.71 - Nasdaq

Kymera Therapeutics (KYMR) Price Target Increased by 11.33% to 77.71  Nasdaq

Kymera Therapeutics (KYMR) Price Target Increased by 11.33% to 77.71 - Nasdaq

Click here to get full coverage on Jefferies Raises Price Target for Kymera Therapeutics (KYMR) to - GuruFocus

Jefferies Raises Price Target for Kymera Therapeutics (KYMR) to  GuruFocus

Jefferies Raises Price Target for Kymera Therapeutics (KYMR) to - GuruFocus

Click here to get full coverage on KYMR Stock Rating: Mizuho Raises Price Target to $120 | KYMR Sto - GuruFocus

KYMR Stock Rating: Mizuho Raises Price Target to $120 | KYMR Sto  GuruFocus

KYMR Stock Rating: Mizuho Raises Price Target to $120 | KYMR Sto - GuruFocus

Click here to get full coverage on B. Riley Securities Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Raises Target Price to $117 - 富途牛牛

B. Riley Securities Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Raises Target Price to $117  富途牛牛

B. Riley Securities Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Raises Target Price to $117 - 富途牛牛

Click here to get full coverage on Kymera Therapeutics (KYMR) Up 10.2% Since Last Earnings Report: Can It Continue? - Nasdaq

Kymera Therapeutics (KYMR) Up 10.2% Since Last Earnings Report: Can It Continue?  Nasdaq

Kymera Therapeutics (KYMR) Up 10.2% Since Last Earnings Report: Can It Continue? - Nasdaq

Click here to get full coverage on Earnings To Watch: Kymera Therapeutics Inc (KYMR) Reports Q2 2025 Result - Yahoo Finance

Earnings To Watch: Kymera Therapeutics Inc (KYMR) Reports Q2 2025 Result  Yahoo Finance

Earnings To Watch: Kymera Therapeutics Inc (KYMR) Reports Q2 2025 Result - Yahoo Finance

Click here to get full coverage on Prudential Financial Inc. Sells 31,260 Shares of Kymera Therapeutics, Inc. $KYMR - MarketBeat

Prudential Financial Inc. Sells 31,260 Shares of Kymera Therapeutics, Inc. $KYMR  MarketBeat

Prudential Financial Inc. Sells 31,260 Shares of Kymera Therapeutics, Inc. $KYMR - MarketBeat

Click here to get full coverage on Kymera Therapeutics (KYMR): Assessing Valuation Following Promising Preclinical Data for KT-579 in Autoimmune Diseases - Yahoo Finance

Kymera Therapeutics (KYMR): Assessing Valuation Following Promising Preclinical Data for KT-579 in Autoimmune Diseases  Yahoo Finance

Kymera Therapeutics (KYMR): Assessing Valuation Following Promising Preclinical Data for KT-579 in Autoimmune Diseases - Yahoo Finance

Click here to get full coverage on Did KT-621 Fast Track Status Just Shift Kymera Therapeutics' (KYMR) Investment Narrative? - simplywall.st

Did KT-621 Fast Track Status Just Shift Kymera Therapeutics' (KYMR) Investment Narrative?  simplywall.st

Did KT-621 Fast Track Status Just Shift Kymera Therapeutics' (KYMR) Investment Narrative? - simplywall.st

Click here to get full coverage on Kymera Therapeutics director Booth sells $21.7 million in stock - Investing.com

Kymera Therapeutics director Booth sells $21.7 million in stock  Investing.com

Kymera Therapeutics director Booth sells $21.7 million in stock - Investing.com

Click here to get full coverage on Therapeutics (KYMR) Stock Rockets on KT‑621 Eczema Breakthrough, Then Pauses After $500M Share Offering – 9 December 2025 Update - ts2.tech

Therapeutics (KYMR) Stock Rockets on KT‑621 Eczema Breakthrough, Then Pauses After $500M Share Offering – 9 December 2025 Update  ts2.tech

Therapeutics (KYMR) Stock Rockets on KT‑621 Eczema Breakthrough, Then Pauses After $500M Share Offering – 9 December 2025 Update - ts2.tech

Click here to get full coverage on Kymera Therapeutics (KYMR) Stock Soars on KT‑621 Eczema Data: What December 8, 2025 Means for Investors - ts2.tech

Kymera Therapeutics (KYMR) Stock Soars on KT‑621 Eczema Data: What December 8, 2025 Means for Investors  ts2.tech

Kymera Therapeutics (KYMR) Stock Soars on KT‑621 Eczema Data: What December 8, 2025 Means for Investors - ts2.tech

Click here to get full coverage on Insider Selling: Kymera Therapeutics (NASDAQ:KYMR) Director Sells 6,101 Shares of Stock - MarketBeat

Insider Selling: Kymera Therapeutics (NASDAQ:KYMR) Director Sells 6,101 Shares of Stock  MarketBeat

Insider Selling: Kymera Therapeutics (NASDAQ:KYMR) Director Sells 6,101 Shares of Stock - MarketBeat

Click here to get full coverage on Director’s Major Stock Sale Shakes Up Kymera Therapeutics - TipRanks

Director’s Major Stock Sale Shakes Up Kymera Therapeutics  TipRanks

Director’s Major Stock Sale Shakes Up Kymera Therapeutics - TipRanks

Click here to get full coverage on Kymera Therapeutics (NASDAQ: KYMR) to Present at Piper Sandler, Citi and Evercore Events - Stock Titan

Kymera Therapeutics (NASDAQ: KYMR) to Present at Piper Sandler, Citi and Evercore Events  Stock Titan

Kymera Therapeutics (NASDAQ: KYMR) to Present at Piper Sandler, Citi and Evercore Events - Stock Titan

Click here to get full coverage on Eventide Asset Management LLC Increases Position in Kymera Therapeutics, Inc. $KYMR - MarketBeat

Eventide Asset Management LLC Increases Position in Kymera Therapeutics, Inc. $KYMR  MarketBeat

Eventide Asset Management LLC Increases Position in Kymera Therapeutics, Inc. $KYMR - MarketBeat

Click here to get full coverage on Redmile Group LLC Trims Stock Holdings in Kymera Therapeutics, Inc. $KYMR - MarketBeat

Redmile Group LLC Trims Stock Holdings in Kymera Therapeutics, Inc. $KYMR  MarketBeat

Redmile Group LLC Trims Stock Holdings in Kymera Therapeutics, Inc. $KYMR - MarketBeat

Click here to get full coverage on Mizuho Initiates Coverage of Kymera Therapeutics (KYMR) with Outperform Recommendation - Nasdaq

Mizuho Initiates Coverage of Kymera Therapeutics (KYMR) with Outperform Recommendation  Nasdaq

Mizuho Initiates Coverage of Kymera Therapeutics (KYMR) with Outperform Recommendation - Nasdaq

Click here to get full coverage on Frontier Capital Management Co. LLC Grows Holdings in Kymera Therapeutics, Inc. $KYMR - MarketBeat

Frontier Capital Management Co. LLC Grows Holdings in Kymera Therapeutics, Inc. $KYMR  MarketBeat

Frontier Capital Management Co. LLC Grows Holdings in Kymera Therapeutics, Inc. $KYMR - MarketBeat

Click here to get full coverage on Kymera Therapeutics (KYMR): Valuation Check After KT-621 Phase 1b Success and FDA Fast Track Nod - simplywall.st

Kymera Therapeutics (KYMR): Valuation Check After KT-621 Phase 1b Success and FDA Fast Track Nod  simplywall.st

Kymera Therapeutics (KYMR): Valuation Check After KT-621 Phase 1b Success and FDA Fast Track Nod - simplywall.st

Click here to get full coverage on Kymera (NASDAQ: KYMR) gets FDA Fast Track for KT-621; Phase 2b AD study ongoing - Stock Titan

Kymera (NASDAQ: KYMR) gets FDA Fast Track for KT-621; Phase 2b AD study ongoing  Stock Titan

Kymera (NASDAQ: KYMR) gets FDA Fast Track for KT-621; Phase 2b AD study ongoing - Stock Titan

Click here to get full coverage on Marshall Wace LLP Acquires 67,384 Shares of Kymera Therapeutics, Inc. $KYMR - MarketBeat

Marshall Wace LLP Acquires 67,384 Shares of Kymera Therapeutics, Inc. $KYMR  MarketBeat

Marshall Wace LLP Acquires 67,384 Shares of Kymera Therapeutics, Inc. $KYMR - MarketBeat

Click here to get full coverage on Kymera Had a Big Week. This Secretive Hedge Fund Bought $172 Million of Its Stock. - Barron's

Kymera Had a Big Week. This Secretive Hedge Fund Bought $172 Million of Its Stock.  Barron's

Kymera Had a Big Week. This Secretive Hedge Fund Bought $172 Million of Its Stock. - Barron's

Click here to get full coverage on Kymera Therapeutics Stock Surge: Time to Buy? - StocksToTrade

Kymera Therapeutics Stock Surge: Time to Buy?  StocksToTrade

Kymera Therapeutics Stock Surge: Time to Buy? - StocksToTrade

Click here to get full coverage on Kymera Therapeutics Inc (KYMR) Q2 2025 Earnings Call Highlights: Strategic Collaborations and ... - Yahoo Finance

Kymera Therapeutics Inc (KYMR) Q2 2025 Earnings Call Highlights: Strategic Collaborations and ...  Yahoo Finance

Kymera Therapeutics Inc (KYMR) Q2 2025 Earnings Call Highlights: Strategic Collaborations and ... - Yahoo Finance

Click here to get full coverage on Kymera is a new Outperform at RBC Capital Markets on lead asset - Seeking Alpha

Kymera is a new Outperform at RBC Capital Markets on lead asset  Seeking Alpha

Kymera is a new Outperform at RBC Capital Markets on lead asset - Seeking Alpha

Click here to get full coverage on Maven Securities LTD Takes $2.18 Million Position in Kymera Therapeutics, Inc. $KYMR - MarketBeat

Maven Securities LTD Takes $2.18 Million Position in Kymera Therapeutics, Inc. $KYMR  MarketBeat

Maven Securities LTD Takes $2.18 Million Position in Kymera Therapeutics, Inc. $KYMR - MarketBeat

Click here to get full coverage on Schroder Investment Management Group Reduces Stake in Kymera Therapeutics, Inc. $KYMR - MarketBeat

Schroder Investment Management Group Reduces Stake in Kymera Therapeutics, Inc. $KYMR  MarketBeat

Schroder Investment Management Group Reduces Stake in Kymera Therapeutics, Inc. $KYMR - MarketBeat

Click here to get full coverage on HC Wainwright Has Positive Estimate for KYMR FY2029 Earnings - MarketBeat

HC Wainwright Has Positive Estimate for KYMR FY2029 Earnings  MarketBeat

HC Wainwright Has Positive Estimate for KYMR FY2029 Earnings - MarketBeat

Click here to get full coverage on Kymera Therapeutics prices $602M public offering at $86.00 a share - MSN

Kymera Therapeutics prices $602M public offering at $86.00 a share  MSN

Kymera Therapeutics prices $602M public offering at $86.00 a share - MSN

Click here to get full coverage on Kymera Therapeutics (KYMR) Receives Upgraded Price Target from L - GuruFocus

Kymera Therapeutics (KYMR) Receives Upgraded Price Target from L  GuruFocus

Kymera Therapeutics (KYMR) Receives Upgraded Price Target from L - GuruFocus

Click here to get full coverage on Kymera Therapeutics (NASDAQ:KYMR) Director Bruce Booth Sells 229,809 Shares - MarketBeat

Kymera Therapeutics (NASDAQ:KYMR) Director Bruce Booth Sells 229,809 Shares  MarketBeat

Kymera Therapeutics (NASDAQ:KYMR) Director Bruce Booth Sells 229,809 Shares - MarketBeat

Click here to get full coverage on New Analyst Forecast: $KYMR Given $80 Price Target - Quiver Quantitative

New Analyst Forecast: $KYMR Given $80 Price Target  Quiver Quantitative

New Analyst Forecast: $KYMR Given $80 Price Target - Quiver Quantitative

Click here to get full coverage on Kymera Therapeutics (NASDAQ:KYMR) Shares Gap Up After Analyst Upgrade - MarketBeat

Kymera Therapeutics (NASDAQ:KYMR) Shares Gap Up After Analyst Upgrade  MarketBeat

KYMR

Price Chart

Key Statistics

Technicals

About KYMR

Latest News

Kymera Therapeutics (KYMR) Sees 4% Drop in Stock Price - GuruFocus

Insider Buying: Smart Money Just Spent +$100M on These 3 Stocks - MarketBeat

Kymera Therapeutics (KYMR) Valuation After KT-621 Fast Track Win and Strong Phase 1b BroADen Trial Data - Yahoo Finance

Advanced Charts

Top Gainers

Top Losers